Anavex Life Sciences to Participate at Upcoming Healthcare Conferences
Anavex Life Sciences (NASDAQ: AVXL), a clinical-stage biopharmaceutical company developing treatments for neurological conditions, announced its participation in two upcoming healthcare conferences. CEO Christopher U. Missling will present at the H.C. Wainwright 3rd Annual BioConnect Investor Conference on May 20th, 2025, at 2:30 pm ET, and the H.C. Wainwright 6th Annual Neuro Perspectives Conference on June 17th, 2025, at 7:00 pm ET. Both events will be held in New York City, with webcasts available to firm clients at hcwevents.com.
The company focuses on innovative treatments for various conditions including Alzheimer's disease, Parkinson's disease, schizophrenia, Rett syndrome, and other CNS disorders.
Anavex Life Sciences (NASDAQ: AVXL), un'azienda biofarmaceutica in fase clinica che sviluppa trattamenti per condizioni neurologiche, ha annunciato la sua partecipazione a due prossimi convegni nel settore sanitario. Il CEO Christopher U. Missling presenterà al 3° Annuale BioConnect Investor Conference di H.C. Wainwright il 20 maggio 2025 alle 14:30 ET, e al 6° Annuale Neuro Perspectives Conference di H.C. Wainwright il 17 giugno 2025 alle 19:00 ET. Entrambi gli eventi si terranno a New York City, con webcast disponibili per i clienti della società su hcwevents.com.
L'azienda si concentra su trattamenti innovativi per diverse patologie, tra cui Alzheimer, Parkinson, schizofrenia, sindrome di Rett e altri disturbi del sistema nervoso centrale.
Anavex Life Sciences (NASDAQ: AVXL), una empresa biofarmacéutica en etapa clínica que desarrolla tratamientos para enfermedades neurológicas, anunció su participación en dos próximas conferencias de salud. El CEO Christopher U. Missling presentará en la 3ª Conferencia Anual BioConnect para Inversores de H.C. Wainwright el 20 de mayo de 2025 a las 2:30 pm ET, y en la 6ª Conferencia Anual Neuro Perspectives de H.C. Wainwright el 17 de junio de 2025 a las 7:00 pm ET. Ambos eventos se realizarán en la ciudad de Nueva York, con transmisiones en línea disponibles para clientes de la firma en hcwevents.com.
La compañía se enfoca en tratamientos innovadores para diversas condiciones, incluyendo enfermedad de Alzheimer, enfermedad de Parkinson, esquizofrenia, síndrome de Rett y otros trastornos del sistema nervioso central.
Anavex Life Sciences (NASDAQ: AVXL)는 신경계 질환 치료제를 개발하는 임상 단계의 바이오제약 회사로, 다가오는 두 개의 헬스케어 컨퍼런스에 참여한다고 발표했습니다. CEO 크리스토퍼 U. 미슬링은 2025년 5월 20일 오후 2시 30분(동부시간)에 열리는 H.C. Wainwright 제3회 연례 BioConnect 투자자 컨퍼런스와 2025년 6월 17일 오후 7시(동부시간)에 열리는 H.C. Wainwright 제6회 연례 Neuro Perspectives 컨퍼런스에서 발표할 예정입니다. 두 행사는 모두 뉴욕시에서 개최되며, hcwevents.com에서 회사 고객을 위한 웹캐스트가 제공됩니다.
이 회사는 알츠하이머병, 파킨슨병, 정신분열증, 레트 증후군 및 기타 중추신경계 질환에 대한 혁신적인 치료법 개발에 주력하고 있습니다.
Anavex Life Sciences (NASDAQ : AVXL), une société biopharmaceutique en phase clinique développant des traitements pour les troubles neurologiques, a annoncé sa participation à deux prochaines conférences dans le secteur de la santé. Le PDG Christopher U. Missling présentera lors de la 3e conférence annuelle BioConnect Investor de H.C. Wainwright le 20 mai 2025 à 14h30 ET, ainsi que lors de la 6e conférence annuelle Neuro Perspectives de H.C. Wainwright le 17 juin 2025 à 19h00 ET. Les deux événements se tiendront à New York, avec des webdiffusions disponibles pour les clients de la société sur hcwevents.com.
L'entreprise se concentre sur des traitements innovants pour diverses pathologies, notamment la maladie d'Alzheimer, la maladie de Parkinson, la schizophrénie, le syndrome de Rett et d'autres troubles du système nerveux central.
Anavex Life Sciences (NASDAQ: AVXL), ein biopharmazeutisches Unternehmen in der klinischen Entwicklungsphase, das Behandlungen für neurologische Erkrankungen entwickelt, gab seine Teilnahme an zwei bevorstehenden Gesundheitskonferenzen bekannt. CEO Christopher U. Missling wird am 3. jährlichen BioConnect Investor Conference von H.C. Wainwright am 20. Mai 2025 um 14:30 Uhr ET und am 6. jährlichen Neuro Perspectives Conference von H.C. Wainwright am 17. Juni 2025 um 19:00 Uhr ET präsentieren. Beide Veranstaltungen finden in New York City statt, mit Webcasts, die für Kunden der Firma unter hcwevents.com verfügbar sind.
Das Unternehmen konzentriert sich auf innovative Behandlungen für verschiedene Erkrankungen, darunter Alzheimer, Parkinson, Schizophrenie, Rett-Syndrom und andere Erkrankungen des zentralen Nervensystems.
- None.
- None.
H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQ and H.C. Wainwright 6th Annual Neuro Perspectives Conference
NEW YORK, May 14, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, today announced that its President & Chief Executive Officer, Christopher U. Missling, PhD, will participate at both the H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQ and H.C. Wainwright 6th Annual Neuro Perspectives Conference. Both conferences will take place in New York City (NY).
- H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQ
When: Tuesday, May 20th, 2025 at 2:30 pm ET.
A webcast is available to clients of the firm at https://hcwevents.com/.
- H.C. Wainwright 6th Annual Neuro Perspectives Conference
When: Tuesday, June 17th, 2025 at 7:00 pm ET.
A webcast is available to clients of the firm at https://hcwevents.com/.
About Anavex Life Sciences Corp.
Anavex Life Sciences Corp. (Nasdaq: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of novel therapeutics for the treatment of neurodegenerative, neurodevelopmental, and neuropsychiatric disorders, including Alzheimer's disease, Parkinson's disease, schizophrenia, Rett syndrome, and other central nervous system (CNS) diseases, pain, and various types of cancer. Anavex's lead drug candidate, ANAVEX®2-73 (blarcamesine), has successfully completed a Phase 2a and a Phase 2b/3 clinical trial for Alzheimer's disease, a Phase 2 proof-of-concept study in Parkinson's disease dementia, and both a Phase 2 and a Phase 3 study in adult patients and one Phase 2/3 study in pediatric patients with Rett syndrome. ANAVEX®2-73 is an orally available drug candidate designed to restore cellular homeostasis by targeting SIGMAR1 and muscarinic receptors. Preclinical studies demonstrated its potential to halt and/or reverse the course of Alzheimer's disease. ANAVEX®2-73 also exhibited anticonvulsant, anti-amnesic, neuroprotective, and anti-depressant properties in animal models, indicating its potential to treat additional CNS disorders, including epilepsy. The Michael J. Fox Foundation for Parkinson's Research previously awarded Anavex a research grant, which fully funded a preclinical study to develop ANAVEX®2-73 for the treatment of Parkinson's disease. We believe that ANAVEX®3-71, which targets SIGMAR1 and M1 muscarinic receptors, is a promising clinical stage drug candidate demonstrating disease-modifying activity against the major hallmarks of Alzheimer's disease in transgenic (3xTg-AD) mice, including cognitive deficits, amyloid, and tau pathologies. In preclinical trials, ANAVEX®3-71 has shown beneficial effects on mitochondrial dysfunction and neuroinflammation. Further information is available at www.anavex.com. You can also connect with the Company on Twitter, Facebook, Instagram, and LinkedIn.
Forward-Looking Statements
Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. Actual events or results may differ materially from those projected in any of such statements due to various factors, including the risks set forth in the Company’s most recent Annual Report on Form 10-K filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and Anavex Life Sciences Corp. undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.
For Further Information:
Anavex Life Sciences Corp.
Research & Business Development
Toll-free: 1-844-689-3939
Email: info@anavex.com
Investors:
Andrew J. Barwicki
Investor Relations
Tel: 516-662-9461
Email: andrew@barwicki.com
FAQ
When is Anavex Life Sciences (AVXL) presenting at the H.C. Wainwright BioConnect Conference 2025?
When is AVXL presenting at the H.C. Wainwright Neuro Perspectives Conference 2025?
What diseases is Anavex Life Sciences (AVXL) developing treatments for?
Who is presenting at the H.C. Wainwright conferences for Anavex Life Sciences?
